Myeloma

UNC's Myeloma Program treats multiple myeloma and plasma cell-related disorders including solitary plasmacytoma, POEMS syndrome, AL amyloidosis, Waldenstrom Macroclobulinemia, MGUS, asymptomatic multiple myeloma and Castleman's disease.

The Myeloma Program offers patients and referring physicians access to a complete range of both diagnostic and therapeutic services for the multiple myeloma and other plasma cell disorders. These include chemotherapy, radiation therapy and stem cell transplantation.  Multiple specialists are part of our team, helping you manage side effects and symptoms of multiple myeloma and treatment side effects.

Multiple myeloma is a cancer of the plasma cells.  Plasma cells are found in bone marrow.   In people with myelomas and other plasma cell disorders, abnormal plasma cells (myeloma cells) multiply in the bone marrow, the factory. The result is fewer healthy blood cells (red cells, white cells and platelets). These plasma cells also produce an abnormal protein (a monoclonal, or M, protein) that can cause damage.

Due to the complicated nature of these disorders, our multidisciplinary approach, with input from experts from a number of specialties, allows us to excel in treating these patients. We ensure that expertly developed care is individualized for each patient and delivered in a well-coordinated and caring manner by incorporating specialists from hematology, medical, radiation oncology, pathology, UNC Imaging and Spine Center, the Bone Marrow and Stem Cell Transplantation Program, radiology, and oncology nursing into a single patient care team.